Protective effect of silymarin in streptozotocin-induced diabetic dyslipidaemia in rats |
Sharma, Manju
(Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University))
Pillai, K.K. (Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University)) Anwer, Tarique (Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University)) Najmi, Abul Kalam (Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University)) Haque, Syed Ehtaishamul (Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University)) Sultana, Yasmin (Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University)) |
1 | Witztum L, Steinberg D. (1991) Role of oxidized lowdensity lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792. DOI |
2 | Wybenga DR, Pileggi VJ, Dirstine PH, Di Glorgio J. (1970) Direct manual determination of serum total cholesterol with a single stable reagent. Clin. Chem. 16, 980-984. |
3 | Valsa AK, Ushakumary B, Vijayalakshmi NR. (1995) Effect of catechin on lipid metabolism. J. Clin. Biochem. Nutr. 19, 175-182. DOI ScienceOn |
4 | Warnick GR, Nguyen T, Albers AA. (1985) Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin. Chem. 31, 217-222. |
5 | Shukla R, Gupta S, Gambhir JK ,Prabhu KM , Murthy PS .(2004) Antioxidant effect of aqueos extract of the bark of ficus bengalensis in hypercholesterolemic rabbits, J. Ethnopharmacol. 92, 47-50. DOI ScienceOn |
6 | Shukla, Sharma SB, Puri D, Prabhu KM, Murthy PS. (2000) Medicinal plants for treatment of diabetes mellitus. Ind J. Clin. Biochem. 15, 169-171. DOI ScienceOn |
7 | Schonfeld JV, Weisbrod B, Muller MK. (1997) Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell. Mol. Life Sci. 53, 917-920. DOI |
8 | Schwartz SL. (2006) Diabetes and dyslipidemia. Diabet. Obes. Metab. 8, 355-364. DOI ScienceOn |
9 | Sharma M, Anwer T, Pillai KK, Haque SE, Najmi AK, Sultana Y. (2008) Silymarin, a flavonoid antioxidant, protects streptozotocin-induced lipid peroxidation and β-cell damage in rat pancreas. Orient. Pharm. Exp. Med. 8, 146-153. DOI ScienceOn |
10 | Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ. (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 276, 17527-17535. |
11 | Stamler J, Vaccaro O, Neaton JD, Wentworth D. (1993) Diabetes, other risk factors, and 12-years cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes. Care. 16, 434-444. DOI ScienceOn |
12 | Steinberg D, Parthasaramy S, Cary TE, Khoo JC, Witztum JJ. (1989) Beyond Cholesterol. Modification of low-density lipoprotein that increase its atherogenicity. New Eng. J. Med. 30, 915-914. |
13 | Mourelle M, Muriel P, Favari L, Franco T. (1989) Prevention of CCI4 induced liver cirrhosis by silymarin. Fundament. Clin. Pharmacol. 3, 183-191. DOI ScienceOn |
14 | Tan BK, Tan CH, Pushparaj PN. (2005) Anti-diabetic activity of the semipurified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin induced diabetic rats. Life Sci. 76, 2827-2839. DOI ScienceOn |
15 | Matsuda T, Ferrei K, Todorov I , Kuroda Y, Smith CV, Kandeel F, Muller Y. (2005) Silymarin protects pancreatic beta cells against cytokine–mediated toxicity: implication of C-Jun NH2–terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endrocrinology 146, 175-179. DOI ScienceOn |
16 | Montgomery R. (1957) Determination of Glycogen. Arch. Biochem. Biophys. 67, 378-86. DOI ScienceOn |
17 | Muriel P, Garciapina T, Perez V, Mourelle M. (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 12, 439-442. DOI |
18 | Muriel P, Mourelle M. (1990) Prevention by silymarin of membrane alteration in acute CCl4 liver damages. J. Applied. Toxicol. 10, 275-279. DOI |
19 | Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. (1996) The yin and the yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscl. Thromb. Vascul. Biol. 16, 831-842. DOI ScienceOn |
20 | Paya M, Fernandiz ML, Sanz MJ, Alcaraz MJ. (1993) Effects of phenolic compounds on bromobenzene mediated hepatotoxicity in mice. Xenobiotica 23, 327-333. DOI |
21 | Braham D, Trinder P. (1972) An improved colour reaction for the determination of blood glucose by oxidase system. Analyst 97, 142-144. DOI |
22 | Pyolara K, Pedersen TK, Kjeshus J, Faergeman O Oisson AG, Thorgeirsson G. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20, 614-620. DOI ScienceOn |
23 | Sathishekar D and Subramanian S. (2005) Beneficial effects of momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol. Pharm. Bull. 28, 978-982. DOI ScienceOn |
24 | Bindoli A, Cavallini L, Siliprandi N. (1977) Inhibitory action of silymarin of lipid peroxide formation in rat liver mitochondria and microsomes. Biochem. Pharmacol. 26, 2405-2409. DOI ScienceOn |
25 | Bucolo G, David M. (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin. Chem. 19, 476-482. |
26 | Chait A, Brazg RL, Tribble DL, Witztum JL, Krauss RM. (1993) Susceptibility of small, dense, LDL to oxidative modification in subjects with the atherogenic lipoprotein phenotype pattern B. Am. J. Med. 94, 350-356. DOI ScienceOn |
27 | Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. (2007) Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Ind. J. Pharmacol. 39, 172-179. DOI |
28 | Friedwald WT, Levy RL, Fredrickson DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502. |
29 | Greimel A, Koch H. (1977) Silymarin-an inhibitor of horseradish peroxidase. Experientia 33, 1417-1418. DOI ScienceOn |
30 | Haffner S. (1999) Diabetes, hyperlipidemia, and coronary artery disease. Am. J. Cardiol. 83, 17F-21F. |
31 | Alzaharani T, Marrat S, Haider A. (2003) Management of dyslipidaemia in primary care. Can. J. Cardiol. 3, 356-360. |
32 | Hegele RA. (1999) Paraoxonase-genes and disease. Annual Med. 31, 217-214. DOI ScienceOn |
33 | Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. (2006) The efficacy of silybum marianum (L). Gaertn. (silymarin) in the treatment of type 2 diabetes: a randomized, doubleblind, placebo-controlled, clinical trial. Phytotherapy Res. 20, 1036-1039. DOI ScienceOn |
34 | Adeneye AA, Adeleke TI, Adeneye AK. (2008) Hypoglycemic and hypolipidemic effects of the aqueous fresh leaves extract of Clerodendrum capitatum in Wistar rats. J. Ethnopharmacol. 116, 7-10. DOI ScienceOn |
35 | Anila L, Vijayalakshmi NR. (2002) Flavonoids from Emblica officinalis and Mangifera indica - effectiveness for dyslipidaemia. J. Ethnopharmacol. 79, 81-87. DOI ScienceOn |
36 | Barnett A. (2001) Type 2 diabetes and cardiovascular disease. Nursing Times 97, 33-35. |
37 | Betteridge J. (1997) Lipid disorders in diabetes mellitus. In: Pickup, JC, Williams, G. (Eds.), Textbook of Diabetes, 31, second ed. Blackwell Science, London, pp. 1-55. |
38 | Barrett-Connor E, Grundy SM, Holdbrook MJ. (1982) Plasma lipids and diabetes mellitus in an adult community. Am. J. Epidemiol. 115, 657-663. DOI |
39 | Best J D and O’Neal DN. Diabetic Dyslipidaemia: Current treatment recommendations, Drugs 59, 1101-1110. DOI ScienceOn |
![]() |